Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled.

Slides:

Advertisements

Similar presentations

Use of the insulin pump in treat cystic fibrosis related diabetes Dana S. Hardin, Julie Rice, Mark Rice, Randall Rosenblatt Journal of Cystic Fibrosis.

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations

Donald R. VanDevanter, David J. Pasta, Michael W. Konstan

Dorene F. Balmer, Joan I. Schall, Virginia A. Stallings

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis,

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint D.R. VanDevanter, A. Yegin, W.J. Morgan,

Cirrhosis and other liver disease in cystic fibrosis

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis T.W.V. Daniels, G.B. Rogers, F.A. Stressmann, C.J.

Delayed publication of clinical trials in cystic fibrosis

Pulmonary exacerbations in CF patients with early lung disease

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Laboratory parameter profiles among patients with cystic fibrosis

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A

Physiologic endpoints for clinical studies for cystic fibrosis

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis Alex H. Gifford, Diana M. Alexandru, Zhigang.

Valerie Waters, Eshetu G

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Theresa A. Laguna, Cynthia B. Williams, Kyle R

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

Lung clearance index during hospital admission in school-age children with cystic fibrosis Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Voriconazole therapy in children with cystic fibrosis

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study E.M. Westerman, P.P.H.

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Predictors of non-referral of patients with cystic fibrosisfor lung transplant evaluation in the United States Kathleen J. Ramos, Bradley S. Quon, Kevin.

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation Noa Nezer M. Sc, David Shoseyov, Eitan.

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Presentation transcript:

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial C. Conrad, J. Lymp, V. Thompson, C. Dunn, Z. Davies, B. Chatfield, D. Nichols, J. Clancy, R. Vender, M.E. Egan, L. Quittell, P. Michelson, V. Antony, J. Spahr, R.C. Rubenstein, R.B. Moss, L.A. Herzenberg, C.H. Goss, R. Tirouvanziam Journal of Cystic Fibrosis Volume 14, Issue 2, Pages 219-227 (March 2015) DOI: 10.1016/j.jcf.2014.08.008 Copyright © 2014 Terms and Conditions

Fig. 1 Flow diagram of participants. Journal of Cystic Fibrosis 2015 14, 219-227DOI: (10.1016/j.jcf.2014.08.008) Copyright © 2014 Terms and Conditions

Fig. 2 Mean change from baseline in FEV1 (L) over time by treatment group. The 95% confidence intervals are calculated using one-sample t-tests. Journal of Cystic Fibrosis 2015 14, 219-227DOI: (10.1016/j.jcf.2014.08.008) Copyright © 2014 Terms and Conditions

Fig. 3 Kaplan–Meier plot of time to pulmonary exacerbation. Censored subjects are denoted with ‘tick’ marks. Journal of Cystic Fibrosis 2015 14, 219-227DOI: (10.1016/j.jcf.2014.08.008) Copyright © 2014 Terms and Conditions